Spike Binding Peptide 1 (SBP1), representing amino acids 21-43 of angiotensin-converting enzyme 2 (ACE2), has been utilized in a novel approach involving lipid nanoparticles (LNPs) encapsulated with oseltamivir phosphate and conjugated to SBP1. This formulation aims to investigate the possibility of achieving a controlled, long-term in vivo release of oseltamivir phosphate. Furthermore, a 2% concentration of SBP1 immobilized on crosslinked networks composed of hydroxy acrylate and ethylxanthate ethyl acrylate has demonstrated enhanced in vitro efficiency in capturing the spike glycoprotein of severe acute respiratory coronavirus 2 (SARS-CoV-2), also referred to as the surface glycoprotein.